IDXX

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

High

493.770

Open

490.315

VWAP

490.87

Vol

668.58K

Mkt Cap

39.85B

Low

487.300

Amount

328.19M

EV/EBITDA(TTM)

31.63

Total Shares

82.59M

40.48B

EV/OCF(TTM)

41.81

P/S(TTM)

10.31

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. Its Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. Its LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve the quality and safety of milk.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

1.03B

+8.11%

2.893

+10.44%

1.04B

+7.06%

3.099

+10.68%

1.06B

+5.6%

3.268

+8.2%

Estimates Revision

The market is revising Upward the revenue expectations for IDEXX Laboratories, Inc. (IDXX) for FY2025, with the revenue forecasts being adjusted by 0.28% over the past three months. During the same period, the stock price has changed by 5.76%.

Revenue Estimates for FY2025

Revise Upward

+0.28%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.84%

In Past 3 Month

Stock Price

Go Up

+5.76%

In Past 3 Month

7 Analyst Rating

2.50% Upside

Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 504.00 USD with a low forecast of 420.00 USD and a high forecast of 548.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

3 Hold

0 Sell

Moderate Buy

2.50% Upside

Current: 491.700

Low

420.00

Averages

504.00

High

548.00

2.50% Upside

Current: 491.700

Low

420.00

Averages

504.00

High

548.00

Stifel

Jonathan Block

Hold

Maintains

$450 → $420

2025-04-14

Reason

Stifel

Jonathan Block

Price Target

$450 → $420

2025-04-14

Maintains

Hold

Reason

Piper Sandler

David Westenberg

Hold

Maintains

$435 → $510

2025-02-10

Reason

Piper Sandler

David Westenberg

Price Target

$435 → $510

2025-02-10

Maintains

Hold

Reason

Piper Sandler raised the firm's price target on Idexx Laboratories to $510 from $435 and keeps a Neutral rating on the shares. The firm cites updated estimates and moving forward of its estimate year to 2026 from 2025.

B of A Securities

Michael Ryskin

Hold

Maintains

$475 → $535

2025-02-04

Reason

B of A Securities

Michael Ryskin

Price Target

$475 → $535

2025-02-04

Maintains

Hold

Reason

Barclays

Balaji Prasad

Buy

Maintains

$481 → $520

2025-02-04

Reason

Barclays

Balaji Prasad

Price Target

$481 → $520

2025-02-04

Maintains

Buy

Reason

Morgan Stanley

Erin Wright

Buy

Maintains

$559 → $550

2025-01-29

Reason

Morgan Stanley

Erin Wright

Price Target

$559 → $550

2025-01-29

Maintains

Buy

Reason

Leerink Partners

Daniel Clark

Buy

Initiates

$500

2024-12-02

Reason

Leerink Partners

Daniel Clark

Price Target

$500

2024-12-02

Initiates

Buy

Reason

Leerink analyst Daniel Clark initiated coverage of Idexx Laboratories with an Outperform rating and $500 price target. The firm notes Idexx Laboratories is the dominant player in the veterinarian testing space and has been the best growth story in animal health. The company has benefited from a steady increase in diagnostic testing in pets, complemented by new product launches that have been well-received by veterinarians. Aided by its proprietary MEDACorp survey work, Leerink sees a continued runway of growth for Idexx. Although vet visit volumes are outside the company's control, the firm does note that its survey respondents expect a pickup in volumes, which helps it get comfortable modeling above-consensus revenue and adjusted EPS growth in 2025.

See All Ratings

Valuation Metrics

The current forward P/E ratio for IDEXX Laboratories Inc (IDXX.O) is 39.19, compared to its 5-year average forward P/E of 52.38. For a more detailed relative valuation and DCF analysis to assess IDEXX Laboratories Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

52.38

Current PE

39.19

Overvalued PE

64.84

Undervalued PE

39.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

36.43

Current EV/EBITDA

27.97

Overvalued EV/EBITDA

44.91

Undervalued EV/EBITDA

27.96

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

11.35

Current PS

9.39

Overvalued PS

13.83

Undervalued PS

8.87